WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , Research Publication Rating and Indexing , 

ISSN 2457-0400

Impact Factor  :  6.711

WJAHR Citation

  All Since 2020
 Citation  105  60
 h-index  4  4
 i10-index  3  2

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR April 2025 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • WJAHR: APRIL ISSUE PUBLISHED

    APRIL 2025 Issue has been successfully launched on 1 APRIL 2025.

Best Article Awards

World Journal of Advance Healthcare Research (WJAHR) is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.

Best Article of current issue

Download Article : Click here

Indexing

  Indexing

  • Google Scholar
  • Index Copernicus
  • SOCOLAR, China
  • Research Bible, Fuchu, Tokyo. JAPAN
  • Cosmos Impact Factor
  • Scientific Indexing Services (SIS)
  • UDLedge Science Citation Index
  • International Impact Factor Services
  • International Society for Research Activity (ISRA) Journal Impact Factor (JIF)
  • IFSIJ Measure of Journal Quality
  • Scientific Journal Impact Factor (SJIF)
  • International Scientific Indexing, UAE (ISI) (Under Process)
  • International Impact Factor Services (IIFS)
  • Web of Science Group (Under Process)
  • Directory of Research Journals Indexing
  • Scholar Article Journal Index (SAJI)
  • International Scientific Indexing ( ISI )
  • Academia
  • Scope Database
  • Research Publication Rating and Indexing

Abstract

WHY USFDA APPROVED HYDROXYCHLOROQUINE?

Mahesh M. Deshpande*

ABSTRACT

In the current scenario there is a severe outbreak of Coronavirus disease 2019 (COVID 2019). This outbreak started from China in December 2019.From there this infectious disease outbreaks worldwide up to April 9, 2020.The World Health Organization declares this as a worldwide pandemic. The current news shows how the infection spreads over USA, Italy and Spain, India and more than ninety countries of the world. Recently on March 28,2020 US FDA approves Hydroxychloroquine and Chloroquine for the treatment of COVID 19. There are few invitro reports are available with these antimalarial drugs that confirms the use for treatment of COVID 2019, but no evidence of clinical trials. The current viewpoint trying to explain both the situation that why these antimalarial drugs can be used for treatment and why the exclusive use should be prohibited.

[Full Text Article] [Download Certificate]